Comparison of Outcomes in Patients Requiring Mechanical Circulatory Support Who Received Cangrelor in Addition to Anticoagulation Versus Anticoagulation Alone
Research article published in Journal of cardiothoracic and vascular anesthesia (2024)
Abstract
OBJECTIVES: To evaluate the safety of cangrelor administered concurrently with heparin or bivalirudin in patients on mechanical circulatory support. DESIGN: A single-center, retrospective cohort study of adult patients consecutively admitted between January 2016 and October 2020. SETTING: A tertiary medical center. PARTICIPANTS: Adult patients admitted to the cardiovascular intensive care unit put on mechanical circulatory support for acute myocardial infarction (AMI) or non-AMI indications. Patients who received cangrelor underwent percutaneous coronary intervention with stenting during the index event or within the last year. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome was the incidence of major bleeding, defined by the Extracorporeal Life Support Organization criteria, in patients with mechanical circulatory support receiving cangrelor plus anticoagulation with heparin or bivalirudin with or without aspirin versus patients who did not receive cangrelor. Sixty-eight patients were included in the study. Twenty-nine patients received cangrelor, and 39 did not. Cangrelor was not associated with an increase in major bleeding; however, the CI was wide (adjusted hazard ratio 1.93, 95% CI 0.61-6.11; p = 0.262). CONCLUSIONS: Patients receiving cangrelor did not appear to be at higher risk of major bleeding compared to patients not receiving cangrelor. Larger trials should be conducted to better evaluate the safety of cangrelor in patients with mechanical circulatory support.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
To evaluate the safety of cangrelor administered concurrently with heparin or bivalirudin in patients on mechanical circulatory support.
Por qué esto importa para la hirudoterapia
Este estudio de cohorte retrospectivo de un solo centro evaluó la seguridad de añadir cangrelor a la anticoagulación (heparina o bivalirudina) en 68 pacientes con soporte circulatorio mecánico, sin encontrar un aumento significativo en el sangrado mayor con el uso de cangrelor, aunque los intervalos de confianza fueron amplios. El estudio es un análisis comparativo de farmacología/seguridad centrado en combinaciones de antiplaquetarios y anticoagulantes en pacientes cardíacos en estado crítico. La bivalirudina aparece como uno de los anticoagulantes comparadores. El resumen no contiene ninguna mención a sanguijuelas, hirudoterapia, hirudina o el secretoma de la sanguijuela; concierne a la seguridad de antiplaquetarios y anticoagulantes en el soporte circulatorio mecánico. No existe una relevancia justificable para el dominio de la ASH, y este artículo se incluye únicamente por exhaustividad.
Citación
Comparison of Outcomes in Patients Requiring Mechanical Circulatory Support Who Received Cangrelor in Addition to Anticoagulation Versus Anticoagulation Alone
Martin TC et al. · Journal of cardiothoracic and vascular anesthesia, 2024
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026